Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 6/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MTR | Q99707 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037447 | 0.89 | MTTP (0.56) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7048300 | 0.88 | MTTP (0.55) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7037440 | 0.87 | MTTP (0.55) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7039387 | 0.86 | MTTP (0.54) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7035909 | 0.86 | MTTP (0.55) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7051970 | 0.86 | MTTP (0.57) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7051107 | 0.86 | MTTP (0.53) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7045205 | 0.86 | MTTP (0.53) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7606909 | 0.86 | KDM4E (0.45) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL7049164 | 0.85 | MTTP (0.53) | MTTPCHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | claimed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | MTTP 1/4885CHRM2 4129/4885ADRA2A 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.